Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ISTA Pharmaceuticals |
---|---|
Information provided by: | ISTA Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00198419 |
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.
Condition | Intervention | Phase |
---|---|---|
Drug Hypersensitivity |
Drug: Vitrase (ovine hyaluronidase); Sterile saline |
Phase I |
Study Type: | Observational |
Study Design: | Cross-Sectional, Defined Population, Prospective Study |
Official Title: | Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Open Label, Normal Volunteer Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Solano Clinical Research (A Division of Dow Pharmaceutical Sciences) | |
Davis, California, United States, 95616 |
Study Director: | Lisa R Grillone, PhD | ISTA Pharmaceuticals, Inc. |
Study ID Numbers: | ISTA-VIT-CS04 |
Study First Received: | September 13, 2005 |
Last Updated: | January 15, 2007 |
ClinicalTrials.gov Identifier: | NCT00198419 |
Health Authority: | United States: Food and Drug Administration |
Hypersensitivity Drug Hypersensitivity |
Immune System Diseases |